Windtree Current Deferred Revenue vs Capital Surpluse Analysis

WINT Stock

USD 0.50 0.01 1.96%

Windtree Therapeutics financial indicator trend analysis is more than just analyzing Windtree Therapeutics current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Windtree Therapeutics is a good investment. Please check the relationship between Windtree Therapeutics Current Deferred Revenue and its Capital Surpluse accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Windtree Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Windtree Stock please use our How to Invest in Windtree Therapeutics guide.

Current Deferred Revenue vs Capital Surpluse

Current Deferred Revenue vs Capital Surpluse Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Windtree Therapeutics Current Deferred Revenue account and Capital Surpluse. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Windtree Therapeutics' Current Deferred Revenue and Capital Surpluse is -0.27. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Capital Surpluse in the same time period over historical financial statements of Windtree Therapeutics, assuming nothing else is changed. The correlation between historical values of Windtree Therapeutics' Current Deferred Revenue and Capital Surpluse is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Windtree Therapeutics are associated (or correlated) with its Capital Surpluse. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Surpluse has no effect on the direction of Current Deferred Revenue i.e., Windtree Therapeutics' Current Deferred Revenue and Capital Surpluse go up and down completely randomly.

Correlation Coefficient

-0.27

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Capital Surpluse

Most indicators from Windtree Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Windtree Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Windtree Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Windtree Stock please use our How to Invest in Windtree Therapeutics guide.At this time, Windtree Therapeutics' Tax Provision is comparatively stable compared to the past year. Issuance Of Capital Stock is likely to gain to about 16.6 M in 2024, whereas Enterprise Value Multiple is likely to drop (0.80) in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	114K	53K	50K	47.5K
Depreciation And Amortization	869K	1.1M	82K	77.9K

Interest Expense Depreciation And Amortization

Windtree Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Property Plant And Equipment Net	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Total Equity	Other Current Assets	Property Plant And Equipment Gross	Common Stock	Non Currrent Assets Other	Inventory	Other Liab	Current Deferred Revenue
Total Assets		0.24	0.06	0.24	0.96	-0.46	-0.36	0.21	0.21	0.71	0.47	0.73	0.45	-0.26	0.28	0.38	0.85	0.45	-0.32	0.21	0.03	-0.32	-0.2	-0.39	0.69	-0.17
Short Long Term Debt Total	0.24		0.67	0.54	0.04	0.03	-0.24	0.62	0.15	0.49	0.23	0.65	0.35	0.42	-0.33	0.3	0.06	0.35	-0.35	-0.1	-0.13	-0.35	0.5	-0.5	-0.08	-0.14
Other Current Liab	0.06	0.67		0.87	-0.05	-0.23	0.06	0.64	-0.38	0.07	-0.08	0.38	0.48	0.55	-0.25	0.45	-0.19	0.49	-0.44	-0.35	-0.41	-0.44	0.48	-0.32	-0.46	0.39
Total Current Liabilities	0.24	0.54	0.87		0.15	-0.14	0.01	0.79	-0.35	0.1	0.0	0.46	0.33	0.46	-0.27	0.24	0.1	0.34	-0.44	-0.41	-0.42	-0.44	0.31	-0.31	-0.18	0.46
Total Stockholder Equity	0.96	0.04	-0.05	0.15		-0.59	-0.15	0.07	0.13	0.53	0.27	0.52	0.5	-0.44	0.27	0.43	0.78	0.5	-0.15	0.19	-0.03	-0.15	-0.31	-0.16	0.61	-0.15
Net Debt	-0.46	0.03	-0.23	-0.14	-0.59		-0.23	0.1	0.32	0.01	0.15	-0.03	-0.91	0.51	-0.22	-0.92	0.01	-0.91	0.11	0.02	0.2	0.11	0.03	-0.06	0.18	-0.12
Retained Earnings	-0.36	-0.24	0.06	0.01	-0.15	-0.23		-0.13	-0.51	-0.7	-0.99	-0.64	0.14	-0.11	-0.56	0.13	-0.45	0.12	0.76	-0.13	-0.61	0.76	0.06	0.9	-0.63	-0.08
Accounts Payable	0.21	0.62	0.64	0.79	0.07	0.1	-0.13		-0.16	0.28	0.12	0.55	0.13	0.44	-0.39	0.06	0.18	0.14	-0.34	-0.15	-0.38	-0.34	0.49	-0.36	-0.05	0.21
Common Stock Shares Outstanding	0.21	0.15	-0.38	-0.35	0.13	0.32	-0.51	-0.16		0.28	0.55	0.15	-0.28	-0.22	0.34	-0.26	0.33	-0.28	-0.17	-0.06	0.78	-0.17	-0.29	-0.29	0.59	-0.18
Non Current Liabilities Total	0.71	0.49	0.07	0.1	0.53	0.01	-0.7	0.28	0.28		0.72	0.93	0.12	0.16	0.21	0.09	0.73	0.13	-0.46	0.45	0.1	-0.46	0.08	-0.71	0.67	-0.31
Other Stockholder Equity	0.47	0.23	-0.08	0.0	0.27	0.15	-0.99	0.12	0.55	0.72		0.67	-0.07	0.03	0.59	-0.07	0.52	-0.05	-0.76	0.14	0.63	-0.76	-0.11	-0.88	0.7	0.06
Total Liab	0.73	0.65	0.38	0.46	0.52	-0.03	-0.64	0.55	0.15	0.93	0.67		0.22	0.31	0.1	0.16	0.69	0.23	-0.59	0.24	-0.03	-0.59	0.18	-0.77	0.54	-0.11
Total Current Assets	0.45	0.35	0.48	0.33	0.5	-0.91	0.14	0.13	-0.28	0.12	-0.07	0.22		-0.3	0.05	0.99	-0.08	1.0	-0.22	-0.05	-0.21	-0.22	0.21	-0.12	-0.25	0.04
Short Term Debt	-0.26	0.42	0.55	0.46	-0.44	0.51	-0.11	0.44	-0.22	0.16	0.03	0.31	-0.3		-0.36	-0.32	-0.09	-0.3	-0.14	-0.06	-0.32	-0.14	0.26	-0.23	-0.19	0.04
Property Plant And Equipment Net	0.28	-0.33	-0.25	-0.27	0.27	-0.22	-0.56	-0.39	0.34	0.21	0.59	0.1	0.05	-0.36		0.11	0.24	0.07	-0.53	0.17	0.65	-0.53	-0.28	-0.44	0.38	0.29
Cash	0.38	0.3	0.45	0.24	0.43	-0.92	0.13	0.06	-0.26	0.09	-0.07	0.16	0.99	-0.32	0.11		-0.15	0.99	-0.23	-0.03	-0.16	-0.24	0.22	-0.12	-0.3	0.07
Non Current Assets Total	0.85	0.06	-0.19	0.1	0.78	0.01	-0.45	0.18	0.33	0.73	0.52	0.69	-0.08	-0.09	0.24	-0.15		-0.07	-0.21	0.29	0.08	-0.21	-0.34	-0.35	0.89	-0.2
Cash And Short Term Investments	0.45	0.35	0.49	0.34	0.5	-0.91	0.12	0.14	-0.28	0.13	-0.05	0.23	1.0	-0.3	0.07	0.99	-0.07		-0.25	-0.07	-0.19	-0.25	0.2	-0.14	-0.25	0.06
Common Stock Total Equity	-0.32	-0.35	-0.44	-0.44	-0.15	0.11	0.76	-0.34	-0.17	-0.46	-0.76	-0.59	-0.22	-0.14	-0.53	-0.23	-0.21	-0.25		0.16	-0.36	1.0	-0.15	0.91	-0.23	-0.57
Other Current Assets	0.21	-0.1	-0.35	-0.41	0.19	0.02	-0.13	-0.15	-0.06	0.45	0.14	0.24	-0.05	-0.06	0.17	-0.03	0.29	-0.07	0.16		-0.01	0.16	0.33	-0.02	0.28	-0.35
Property Plant And Equipment Gross	0.03	-0.13	-0.41	-0.42	-0.03	0.2	-0.61	-0.38	0.78	0.1	0.63	-0.03	-0.21	-0.32	0.65	-0.16	0.08	-0.19	-0.36	-0.01		-0.36	-0.29	-0.37	0.45	0.05
Common Stock	-0.32	-0.35	-0.44	-0.44	-0.15	0.11	0.76	-0.34	-0.17	-0.46	-0.76	-0.59	-0.22	-0.14	-0.53	-0.24	-0.21	-0.25	1.0	0.16	-0.36		-0.15	0.91	-0.23	-0.57
Non Currrent Assets Other	-0.2	0.5	0.48	0.31	-0.31	0.03	0.06	0.49	-0.29	0.08	-0.11	0.18	0.21	0.26	-0.28	0.22	-0.34	0.2	-0.15	0.33	-0.29	-0.15		-0.16	-0.45	0.19
Inventory	-0.39	-0.5	-0.32	-0.31	-0.16	-0.06	0.9	-0.36	-0.29	-0.71	-0.88	-0.77	-0.12	-0.23	-0.44	-0.12	-0.35	-0.14	0.91	-0.02	-0.37	0.91	-0.16		-0.39	-0.23
Other Liab	0.69	-0.08	-0.46	-0.18	0.61	0.18	-0.63	-0.05	0.59	0.67	0.7	0.54	-0.25	-0.19	0.38	-0.3	0.89	-0.25	-0.23	0.28	0.45	-0.23	-0.45	-0.39		-0.26
Current Deferred Revenue	-0.17	-0.14	0.39	0.46	-0.15	-0.12	-0.08	0.21	-0.18	-0.31	0.06	-0.11	0.04	0.04	0.29	0.07	-0.2	0.06	-0.57	-0.35	0.05	-0.57	0.19	-0.23	-0.26

Click cells to compare fundamentals

Windtree Therapeutics Account Relationship Matchups

Windtree Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	119.0M	112.9M	74.8M	38.0M	32.4M	42.3M
Short Long Term Debt Total	20.5M	3.8M	2.9M	2.3M	16.8M	9.8M
Other Current Liab	5.2M	3.0M	2.9M	1.1M	2.5M	2.6M
Total Current Liabilities	7.8M	6.1M	4.9M	2.5M	4.0M	3.8M
Total Stockholder Equity	74.9M	69.6M	41.9M	10.0M	3.4M	3.2M
Net Debt	(16.3M)	(13.1M)	(19.5M)	(3.9M)	12.5M	13.1M
Retained Earnings	(685.1M)	(717.7M)	(785.3M)	(824.5M)	(844.8M)	(802.6M)
Accounts Payable	1.7M	1.2M	693K	249K	809K	768.6K
Common Stock Shares Outstanding	218.6K	20K	30K	40K	220K	231K
Liabilities And Stockholders Equity	119.0M	112.9M	74.8M	38.0M	32.4M	42.3M
Non Current Liabilities Total	36.2M	37.2M	28.0M	25.5M	25.0M	14.1M
Other Stockholder Equity	760.0M	787.2M	827.2M	834.5M	848.2M	890.6M
Total Liab	44.0M	43.3M	32.9M	27.9M	29.0M	21.5M
Total Current Assets	23.9M	18.1M	23.5M	7.4M	5.4M	5.1M
Short Term Debt	911K	2.0M	1.4M	1.1M	669K	635.6K
Property Plant And Equipment Net	2.2M	1.8M	3.4M	2.1M	1.6M	2.5M
Cash	22.6M	16.9M	22.3M	6.2M	4.3M	4.1M
Non Current Assets Total	95.1M	94.8M	51.3M	30.6M	27.0M	18.0M
Cash And Short Term Investments	22.6M	16.9M	22.3M	6.2M	4.3M	4.1M
Common Stock Total Equity	3K	32K	41K	17K	15.3K	14.5K
Other Current Assets	1.3M	2.4M	2.3M	1.2M	1.1M	956.1K
Property Plant And Equipment Gross	2.2M	1.8M	3.4M	2.1M	5.4M	5.6M
Common Stock	41K	17K	28K	6K	5.4K	5.1K
Other Liab	15.7M	15.8M	19.6M	10.9M	12.6M	13.2M
Property Plant Equipment	802K	798K	1.8M	3.4M	3.1M	2.1M
Net Tangible Assets	52.4M	(17.8M)	(23.2M)	(5.9M)	(5.3M)	(5.0M)
Retained Earnings Total Equity	(637.1M)	(657.6M)	(685.1M)	(717.7M)	(645.9M)	(678.2M)
Capital Surpluse	616.2M	728.8M	763.1M	790.3M	908.8M	662.9M
Short Long Term Debt	161K	352K	294K	252K	233K	221.4K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Windtree Stock Analysis

When running Windtree Therapeutics' price analysis, check to measure Windtree Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Windtree Therapeutics is operating at the current time. Most of Windtree Therapeutics' value examination focuses on studying past and present price action to predict the probability of Windtree Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Windtree Therapeutics' price. Additionally, you may evaluate how the addition of Windtree Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC